Featured Studies

Researchers are enrolling people with locally advanced or metastatic cancer who are prescribed atezolizumab (alone or with other approved treatments). The study will monitor blood levels to adjust infusion schedules, aiming to see if lower or less frequent doses can be given without reducing effectiveness, over a period of up to 2 years.

Researchers at NCI are developing a new investigational treatment known as TNhYP218 CAR T cells to target and kill tumor cells in people with solid tumors and with those that have high levels of mesothelin (MSLN) including mesothelioma. The study team collects immune cells (T cells); the T cells are genetically modified to target and kill tumor cells to potentially shrink the tumor.

To look at a broad range of traits in people who are healthy people and people with alcohol problems. To study them for potential eligibility for other research protocols conducted at the NIH Clinical Center.

Investigators at the National Cancer Institute (NCI) are enrolling patients with advanced hepatocellular cancers (HCC), in a clinical trial using engineered immune cells, also known as chimeric antigen receptor T-cells or CAR-T cells. In this study, your immune T-cells are collected and modified to target Glypican-3 (GPC3), a protein marker found on the surface of HCC tumors. Researchers hope the altered cells will help identify and fight the cancer cells.

Doctors at the National Cancer Institute (NCI) are looking for volunteers with metastatic cancers, including breast, ovarian, endometrial, gastrointestinal, genitourinary, hepatobiliary, pancreatic, melanoma, non-small cell lung cancer (NSCLC), and multiple myeloma with solid masses. Potential participants will be evaluated with new immunotherapy treatments utilizing cell transfer immunotherapies in a research trial.

Investigators at The National Institutes of Health (NIH) are conducting a research study to understand taste and smell alterations and how they differ in obese versus non-obese individuals.

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.

Researchers at the National Institutes of Health (NIH) Clinical Center seek healthy volunteers for a research study on opioid use disorder (OUD). The purpose of this research study is to learn how opiate use disorder affects dopamine signaling in the brain of people dependent on opioids.